Skip to main content

Advertisement

SpringerLink
Log in

Cabergoline Decreases Somatotroph Adenoma Size: A Case Report

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Dopamine agonists have been shown to reduce growth hormone secretion in some patients with acromegaly, but their effect on adenoma size has not been well appreciated. We describe a 69 year-old woman with acromegaly caused by a somatotroph macroadenoma who received primary treatment with the dopamine agonist cabergoline. Two months after beginning cabergoline, she experienced soft tissue regression and normalization of the serum IGF-1 concentration that persisted for the remainder of the 25 months of observation. By 13 months, the volume of the adenoma by MRI was 28% of its pretreatment size, and by 25 months it was 24%.

This case demonstrates that when cabergoline decreases substantially the serum IGF-1 concentration of a patient with a somatotroph macroadenoma, the adenoma size may also decrease substantially. This demonstration, plus the ease of oral administration, suggests that it would be worthwhile to study systematically the effect of cabergoline on the size of somatotroph macroadenomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ezzat S, Snyder PJ, Young WF, Boyajay LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey Wb, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, Melmed S. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117:711–718.

    CAS  PubMed  Google Scholar 

  2. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87:3013–3018.

    Article  CAS  PubMed  Google Scholar 

  3. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajay LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF, Boyd AE, Sheeler L, Cook D, Malarkey Wb, Jackson IMD, Vance ML, Thorner MO, Ho PJ, Jaffe CA, Frohman LA, Kleinberg DL. Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients—a clinical research center study. J Clin Endocrinol Metab 1995;80:2768–2775.

    Article  CAS  PubMed  Google Scholar 

  4. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034–3040.

    Article  CAS  PubMed  Google Scholar 

  5. Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, Fortini P, Dubini A. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf) 1988;29:467–476.

    CAS  Google Scholar 

  6. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21:713–735.

    CAS  PubMed  Google Scholar 

  7. Colao A, Ferone D, Marzullo P, DiSarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997;82:518–523.

    CAS  PubMed  Google Scholar 

  8. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997;20:537–546.

    CAS  PubMed  Google Scholar 

  9. Jackson SN, Fowler J, Howlett TA. Cabergoline treatment of acromegaly: A preliminary dose finding study. Clin Endocrinol (Oxf) 1997;46:745–749.

    Article  CAS  Google Scholar 

  10. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens J, Mahler C, Beckers A. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 1998;83:374–378.

    Article  CAS  PubMed  Google Scholar 

  11. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli G. Cabergoline in acromegaly: A renewed role for dopamine agonist treatment? Eur J Endocrinol 1998;139:516–521.

    Article  CAS  PubMed  Google Scholar 

  12. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996;44:305–309.

    Article  CAS  Google Scholar 

  13. Petakov MS, Damjanovic SS, Nikolic-Durovic MM, Dragojlovic ZL, Obradovic S, Gligorovic MS, Simic MZ, Popovic VP. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998;21:184–188.

    CAS  PubMed  Google Scholar 

  14. DiChirio G, Nelson KB. The volume of the sella turcica. AJR 1962;87:989–980.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania School of Medicine, 19104-6149, Philadelphia, PA, USA

    Michael R. Rickels & Peter J. Snyder

Authors
  1. Michael R. Rickels
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rickels, M.R., Snyder, P.J. Cabergoline Decreases Somatotroph Adenoma Size: A Case Report. Pituitary 7, 107–110 (2004). https://doi.org/10.1007/s11102-005-5353-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-005-5353-1

Key Words

Search

Navigation